<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is the most prevalent <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> in man </plain></SENT>
<SENT sid="1" pm="."><plain>Incidence increases with age, risk of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> as a result of AF disproportionally so </plain></SENT>
<SENT sid="2" pm="."><plain>Anticoagulation is therefore one of the cornerstones of treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Perceived severity of <z:mp ids='MP_0001914'>bleeding</z:mp> risk on <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> is, however, one of the main reasons that the elderly population at highest risk is relatively undertreated.This article describes both risks for the traditional <z:chebi fb="6" ids="28384">vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi>,in addition to the new direct thrombin and factor Xa <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
</text></document>